ADC	Antibody–drug conjugate
ADCC	Antibody-dependent cellular cytotoxicity
ADCP	Antibody-dependent cellular phagocytosis
BiTE	Bispecific T-cell engager
CAR-T	Chimeric antigen receptor T-cell
CD3	Cluster of differentiation 3
CDC	Complement-dependent cytotoxicity
CI	Confidence interval
CLDN18.2	Claudin 18.2
CPS	Combined positive score
CR	Complete response
CRS	Cytokine release syndrome
ctDNA	Circulating tumour DNA
DCR	Disease control rate
DOR	Duration of response
EGF	Epidermal growth factor
EGFR	Epidermal growth factor receptor
EMA	European Medicines Agency
FDA	Food and Drug Administration
FGFR2b	Fibroblast growth factor receptor 2
G	Gastric
GCN	Gene copy number
GEA	Gastroesophageal adenocarcinoma
GOJ	Gastroesophageal junction
HER2	Human epidermal growth factor receptor 2
HGF	Hepatocyte growth factor
HLH	Haemophagocytic lymphohistiocytosis
HR	Hazard ratio
ICI	Immune checkpoint inhibitor
ICANS	Immune effector cell-associated neurotoxicity syndrome
IHC	Immunohistochemistry
ISH	In situ hybridisation
LVEF	Left ventricular ejection fraction
mAb	Monoclonal antibody
MET	Mesenchymal-epithelial transition factor
MMAE	Monomethyl auristatin E
dMMR	Mismatch repair deficiency
NMPA	National Medical Products Administration
NGS	Next generation sequencing
NSCLC	Non-small cell lung cancer
ORR	Objective response rate
OS	Overall survival
PD-1	Programmed cell death protein 1
PD-L1	Programmed cell death-ligand 1
PFS	Progression-free survival
TAP	Tumour area positivity
TGF-α	Transforming growth factor-α
THBS1	Thrombospondin-1
TKI	Tyrosine kinase inhibitor
TRAE	Treatment-related adverse event
US	United States
VEGF	Vascular endothelial growth factor
VEGFR2	Vascular endothelial growth factor receptor 2